Last A$0.0065 AUD
Change Today 0.00 / 0.00%
Volume 0.0
IMC On Other Exchanges
Symbol
Exchange
OTC US
As of 10:30 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

immuron ltd (IMC) Snapshot

Open
A$0.0065
Previous Close
A$0.0065
Day High
A$0.0065
Day Low
A$0.0065
52 Week High
11/13/13 - A$0.02
52 Week Low
05/9/14 - A$0.0040
Market Cap
19.5M
Average Volume 10 Days
3.6M
EPS TTM
A$-0.0012
Shares Outstanding
3.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMURON LTD (IMC)

Related News

No related news articles were found.

immuron ltd (IMC) Related Businessweek News

No Related Businessweek News Found

immuron ltd (IMC) Details

Immuron Limited, a biopharmaceutical company, researches, develops, and sells polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. Its platform technology enables the development of medicines that target a range of medical needs, such as infectious diseases, immune mediated disorders, and cancers. The company commercializes its platform derived products through a range of regulatory pathways, including prescription, medical foods, over-the-counter medicines, and dietary supplements. It markets Travelan, a natural product to prevent infection by enterotoxigenic escherichia coli, which is the cause of travellers’ diarrhoea. The company is also developing IMM 124-E, a natural product for the treatment of fatty liver and non-alcoholic steatohepatitis/Type 2 diabetes, which is under Phase II clinical trial; IMM 529 for the treatment of clostridium difficile infection; IMM-363 to treat of side effects caused by chemotherapy or radiation; and IMM-160 to reduce tumour size and suppress liver cancer. Immuron Limited was founded in 1994 and is based in Southbank, Australia.

16 Employees
Last Reported Date: 08/29/14
Founded in 1994

immuron ltd (IMC) Top Compensated Officers

Chief Executive Officer and Vice President of...
Total Annual Compensation: A$220.0K
External Advisor
Total Annual Compensation: A$192.0K
Chief Scientific Officer
Total Annual Compensation: A$102.9K
Compensation as of Fiscal Year 2014.

immuron ltd (IMC) Key Developments

Immuron Limited Reports Earnings Results for the Full Year Ended June 30, 2014

Immuron Limited reported earnings results for the full year ended June 30, 2014. For the year, the company reported total revenue of AUD 1,044,142 compared to AUD 149,755 a year ago. Loss before income tax attributable to members of company was of AUD 2,544,550 compared to AUD 3,539,117 a year ago. Loss was AUD 2,544,550 or 0.152 cents per diluted share compared to AUD 3,539,117 or 0.698 cents per diluted share a year ago. Net cash flows used in operating activities was AUD 2,650,577 compared to AUD 2,045,407 a year ago. Payment for purchases of plant and equipment was of AUD 15,901 compared to AUD 7,200 a year ago.

Immuron Limited Presents at 2014 Bioshares Biotech Summit, Jul-18-2014 02:40 PM

Immuron Limited Presents at 2014 Bioshares Biotech Summit, Jul-18-2014 02:40 PM. Venue: Rydges Lakeland Resort, Queenstown, New Zealand. Speakers: Amos Meltzer, Chief Executive Officer and Vice President of Business Development.

Immuron Limited Presents at 2014 Asia Biotech Invest Conference, Jun-05-2014 03:00 PM

Immuron Limited Presents at 2014 Asia Biotech Invest Conference, Jun-05-2014 03:00 PM. Venue: Sheraton Hong Kong Hotel & Towers, 20 Nathan Road, Kowloon, Hong Kong. Speakers: Amos Meltzer, Chief Executive Officer and Vice President of Business Development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMC:AU A$0.01 AUD 0.00

IMC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMC.
View Industry Companies
 

Industry Analysis

IMC

Industry Average

Valuation IMC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.3x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMURON LTD, please visit www.immuron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.